← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Virtici, Llc
Seattle, WA
$26,065,534
Total funding
29
Grants
Funding over time
peak $3.2M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,915,534 · 28
CDC$150,000 · 1
By mechanism
R44$12,137,780 · 6
R43$9,162,200 · 20
UT2$3,580,622 · 1
N43$599,582 · 1
N01$585,350 · 1
Investigators at Virtici, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$1,455,915
UT2 · FY2019 · GM
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$1,374,707
UT2 · FY2020 · GM
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$1,049,994
R44 · FY2024 · HL
A Novel Peptide Therapeutic for Obesity$1,000,985
R44 · FY2017 · DK
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$1,000,000
R44 · FY2017 · AI
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$999,989
R44 · FY2025 · HL
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$994,179
R44 · FY2021 · AI
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$990,104
R44 · FY2018 · AI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$979,534
R44 · FY2022 · AI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$978,755
R44 · FY2023 · AI
A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection$923,623
R44 · FY2024 · DE
A Novel Peptide Therapeutic for Obesity$829,401
R44 · FY2018 · DK
A Novel Blood Test for Early Diagnosis of Frontotemporal Lobar Degeneration$700,000
R43 · FY2024 · NS
A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection$698,684
R44 · FY2025 · DE
A Novel Tolerance Therapeutic to Treat Asthma$689,961
R43 · FY2012 · HL
DEVELOPMENT OF TOLL-LIKE RECEPTOR AGONISTS TO STRENGTHEN SUBLINGUAL VACCINES.$599,582
N43 · FY2022 · AI
A Novel Adjuvant-based Probiotic Platform for Generating Tolerance Therapeutics$585,350
N01 · FY2018 · AI
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$500,000
UT2 · FY2018 · GM
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$479,708
R44 · FY2016 · AI
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$441,280
R43 · FY2022 · AG